Pricing Log in Create free account
Saturday 17 October 2026 Export GMAB’s income statement to Excel — free account

Genmab A/S Sponsored ADR

GMAB Healthcare Biotechnology

Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024. In the quarter to June 2026, revenue grew 24.9%, EPS fell 9.26% and free cash flow fell 7.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

37.00 0.82 −2.17%
Market cap
$22.6B
P/E
29.1×
Fwd P/E
21.0×
Dividend yield
—
F-score
4/9
Altman Z
2.78
Beneish M
−3.00
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 4.28%

Capital & Financial Ratios $m

Market Cap 22,600.00
Revenue 4,131.00
Net Income 906.00
Free Cash Flow (6,347.00)
Net Debt 3,632.00
Current Ratio 2.46 (at or above 1.5: strong)
Debt/Equity 0.86
P/E ratio 29.13
Fwd P/E 21.00
P/S ratio 5.49
P/B ratio 3.81
Past 5Y EPS Growth 6.58%
This Y EPS Growth (23.23%) (below 0%: weak)
Next Y EPS Growth 46.34% (at or above 15%: strong)
Next Y revenue growth 19.13% (at or above 10%: strong)
Next 5Y EPS Growth 21.18% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.4×, against a ten-year median of 10.3×; over the ten years it ranged from 2.9× in 2025 to 24.0× in 2019.
P/E against its own 10 years 63.15%
10-year low 10-year high
P/S against its own 10 years 26.69%
10-year low 10-year high
P/B against its own 10 years 34.08%
10-year low 10-year high
EV/Sales against its own 10 years 37.70%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 4,085 2,954 1,715 1,503
Receivables 718 937 1,152 1,280
Inventory 8 9 18 18
Other — — — —
4,812 3,900 2,885 2,801
2023 2024 2025 Q'26
Payables — — — —
ST’ Debt — — 273 294
Other — 3 24 21
361 744 1,427 1,140

Compound Annual Growth %

10y 5y 3y
Sales — 19.15% 21.64%
Cash Flow — 3.77% 28.89%
Earnings — 5.73% 7.19%
Book Value — 14.82% 14.59%

Revenue $m

Mar Jun Sep Dec Year
’26 896 1,155 — — —
’25 715 925 1,022 1,058 3,720
’24 603 779 816 923 3,121
’23 411 613 693 675 2,392
’22 320 452 553 742 2,067
’21 256 320 366 407 1,349
’20 132 805 271 341 1,549
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 51 — — —
’25 287 62 536 301 1,186
’24 219 219 299 389 1,126
’23 466 70 297 238 1,072
’22 89 133 254 78 554
’21 192 58 66 39 354
’20 324 (6) 817 (150) 986
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 48 — — —
’25 257 52 534 (6,927) (6,084)
’24 215 215 292 346 1,055
’23 451 54 283 219 1,017
’22 80 123 244 17 509
’21 188 45 54 18 314
’20 315 (27) 808 (166) 939
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.08 0.49 — — —
’25 0.31 0.54 0.65 0.05 1.54
’24 0.29 0.31 0.29 0.85 1.76
’23 0.05 0.30 0.47 0.14 0.96
’22 0.11 0.41 0.53 0.12 1.15
’21 0.27 0.08 0.21 0.17 0.72
’20 0.06 0.76 0.13 0.14 1.12
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 9.23 16.21 12.10 14.48 16.24 30.10 26.19 27.74 19.85 17.24

Analyst estimates 2026–2028

Powerpack
High 19.41 23.55 103.19 24.50 41.50 49.07 47.50 43.66 32.88 33.96
People
People Employees — — 419 548 781 1,212 1,660 2,204 2,682 3,029
Revenue/emp, $m 0.00 0.00 1.14 1.47 1.98 1.11 1.24 1.09 1.16 1.23
Income, $m
Income, $m Revenue 258 381 479 804 1,549 1,349 2,067 2,392 3,121 3,720
Gross margin, % 0.00 0.00 100.00 100.00 100.00 100.00 100.00 98.63 95.42 93.60
EBT 160 171 255 429 904 634 996 818 1,326 1,204
EBT margin, % 62.22 44.99 53.29 53.28 58.39 46.96 48.20 34.22 42.49 32.37
Net income 168 0 255 429 904 634 996 818 1,326 1,204
Depreciation 6 11 14 21 40 39 51 43 60 71
Per share, $
Per share, $ Revenue 0.43 0.62 0.78 1.28 2.38 2.06 3.16 3.66 4.86 5.99
Earnings 2.81 2.92 0.38 0.52 1.12 0.73 1.16 0.97 1.77 1.55
Cash flow 0.08 0.41 0.26 0.32 1.51 0.54 0.85 1.64 1.75 1.91
Capex 0.00 0.00 (0.12) (0.03) (0.07) (0.06) (0.07) (0.08) (0.11) (11.70)
Free cash flow 0.08 0.41 0.14 0.29 1.44 0.48 0.78 1.56 1.64 (9.79)
Book value 1.13 1.63 2.07 3.34 4.49 5.40 5.94 7.03 8.00 9.41
Shares, m 604 619 613 630 652 654 654 653 642 622
Valuation, ×
Valuation, × P/E 6.11 2.99 7.73 33.54 36.96 53.46 36.47 33.10 11.79 19.87
P/S 0.00 0.00 0.00 17.48 17.11 19.17 13.61 8.77 4.29 5.15
P/B 0.81 0.81 0.81 6.68 9.05 7.33 7.24 4.57 2.61 3.27
EV/Sales 0.00 0.00 0.00 15.47 15.55 16.94 12.13 7.11 3.38 6.10
EV/FCF 0.00 0.00 0.00 34.61 25.89 77.35 55.29 17.66 9.88 (3.73)
Cash, $m
Cash, $m Operating cash flow 47 256 161 199 986 354 554 1,072 1,126 1,186
Capex (5) (14) (76) (17) (47) (40) (45) (55) (71) (7,270)
Free cash flow 47 256 85 182 939 314 509 1,017 1,055 (6,084)
Balance, $m
Balance, $m Working capital 636 923 1,107 1,952 2,687 3,368 3,760 4,451 3,156 1,458
Total debt — — — 27 53 65 86 — — 5,274
Net debt (556) (873) (967) (1,617) (2,411) (3,012) (3,075) (4,085) (2,954) 3,559
Shareholders’ equity 685 1,010 1,269 2,106 2,929 3,531 3,886 4,590 5,137 5,847
Returns, %
Returns, % ROA 18.64 47.86 22.39 17.99 26.46 13.37 19.06 13.43 19.64 9.99
ROIC 0.00 0.00 45.21 50.60 116.54 57.78 69.44 95.70 27.83 7.08
ROE 19.87 20.98 20.46 19.24 28.95 14.81 21.08 14.91 23.30 17.53
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Genmab A/S Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RPRX Royalty Pharma PLC $34.3B 42.3× 21.9× +16.50% (above 0%: growing) −40.00% (below 0%: shrinking) +31.57% (above 0%: growing) 100.00% 19.75% Compare
ALNY Alnylam Pharmaceuticals, Inc. $31.3B 39.5× 39.6× +66.86% (above 0%: growing) n/m +152.82% (above 0%: growing) 76.88% 17.93% Compare
ROIV Roivant Sciences Ltd. $24.6B — (loss-making) — (loss-making) −33.55% (below 0%: shrinking) n/m −29.99% (below 0%: shrinking) 80.31% (25,380.93%) Compare
INCY Incyte Corporation $23.0B 13.9× 15.6× +37.72% (above 0%: growing) +39.71% (above 0%: growing) +1,829.52% (above 0%: growing) 93.73% 41.69% Compare
BNTX BioNTech SE Sponsored ADR $22.7B — (loss-making) — (loss-making) −58.53% (below 0%: shrinking) n/m −342.04% (below 0%: shrinking) 8.14% (897.82%) Compare
GMAB Genmab A/S Sponsored ADR $22.6B 29.1× 21.0× +24.86% (above 0%: growing) −9.26% (below 0%: shrinking) −7.69% (below 0%: shrinking) 92.73% 32.47%
INSM Insmed, Inc. $21.7B — (loss-making) — (loss-making) +296.11% (above 0%: growing) n/m +54.52% (above 0%: growing) 84.20% (0.36%) Compare
EXEL Exelixis, Inc. $15.6B 18.8× 16.7× +10.63% (above 0%: growing) +25.00% (above 0%: growing) +557.25% (above 0%: growing) 96.71% 39.51% Compare
ASND Ascendis Pharma A/S $14.9B 16.3× 13.0× +119.88% (above 0%: growing) n/m +2,335.93% (above 0%: growing) 91.85% 64.98% Compare
Median of peers $22.8B 18.8× 16.7× +27.11% +25.00% +103.67% 88.03% 18.84%

All 614 Biotechnology stocks →

Genmab A/S Sponsored ADR (GMAB) key facts

  • Strength: Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
  • Genmab A/S Sponsored ADR (GMAB) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, GMAB traded at $37.00, a market capitalization of $22.6 billion.
  • Return on equity was 17.5% and debt-to-equity 0.86.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.78 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Genmab A/S Sponsored ADR (GMAB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GMAB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com